Originally defined as a high affinity cannabinoid CB1
receptor silent antagonist. Acts as a partial agonist in inhibiting forksolin-induced cyclic AMP stimulation (EC50
= 40.4 nM). Decreases food intake and stimulates locomotor activity in rodents. Antagonizes effects of CP55,940
(Cat. No. 0949) in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from VCU-IPF
Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist.'
Gardner and Mallet
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist.
Wiley et al.
Agonists and silent antagonists in a series of cannabinoid sulfonamides.
Martin et al.
Symposium on the Cannabinoids, International Canna, 2002;
The citations listed below are publications that use Tocris products. Selected citations for O-2050 include:
Showing Results 1 - 7 of 7